Inhibikase Therapeutics reported financial results for the quarter ended June 30, 2025 and highlighted recent developments in their clinical-stage pharmaceutical activities focusing on cardiopulmonary diseases, especially Pulmonary Arterial Hypertension (PAH).
The company is advancing IKT-001 towards a late-stage clinical trial in PAH and has finalized the study protocol for the Phase 2b clinical study.
Key recent activities include evaluating study designs, obtaining feedback from key opinion leaders, and preparing for the IMPROVE-PAH study.
Advancement of IKT-001 in PAH
The company is preparing for the IMPROVE-PAH study, a randomized, double-blind, placebo-controlled trial of IKT-001 in PAH participants with primary endpoints focused on pulmonary vascular resistance and secondary endpoints including 6MWD and pharmacokinetics.
Financial Results Snapshot
As of June 30, 2025, Inhibikase had $87.7 million in cash, cash equivalents, and marketable securities. The net loss for the quarter was $9.9 million, primarily attributed to increased research and development expenses.
R&D and SG&A Expenses
Research and development expenses increased to $5.3 million and selling, general, and administrative expenses rose to $5.9 million for the quarter ended June 30, 2025, reflecting investment in ongoing clinical activities and operational costs.
- The company's focus on advancing IKT-001 in PAH reflects a commitment to addressing unmet medical needs in cardiopulmonary diseases.
- Financially, the decrease in cash position and increase in net loss indicate the company's investment in research and development activities to drive therapeutic innovation in PAH and other related conditions.
Inhibikase Therapeutics' strategic focus on advancing IKT-001 in PAH and the associated financial results demonstrate a commitment to innovative clinical development and addressing critical medical challenges.